Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses ...

A recent study published in the Journal of Cancer Research and Clinical Oncology explored genetic predictors of prostate cancer progression to help identify its clinical outcomes.

A major discovery by Australian researchers of a key driver of prostate cancer could lead to the next generation of targeted ...

Senior doctors responsible for monitoring cancer care in England and Wales are concerned failings in NHS services are ...

Providence Alaska Medical Center will be the first in the state to offer Pluvicto, an innovative therapy for metastatic ...

GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Benjamin Maughan discussing a prospective trial of a structured exercise program to lessen fatigue in patients with ...

“Prostate-specific membrane antigen (PSMA) PET imaging can identify patients suitable for PSMA-targeted radioligand therapy such as lutetium-177-PSMA-617. This is crucial for mCRPC patients who have ...

(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Ivan de Kouchkovsky discussing the impact of baseline PSMA PET in patients with metastatic ...

For patients with advanced prostate cancer (aPC), completion of a 12-week supervised exercise regimen leads to a sign ...

Real-world data suggest that, although guideline-concordant care is on the rise, many US patients with mHSPC may not receive it.

John Ryan, a U.S. Navy veteran, beat cancer through nearly a decade of experimental immunotherapy treatment. The vet shared ...